Aarhus University Seal / Aarhus Universitets segl

Frequency and clonality of peripheral γδ T cells in psoriasis patients receiving anti-TNF-α therapy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Hepatosplenic γδ T cell lymphoma (HSTCL) has been observed in patients with Crohn's disease (CD) who received anti-TNF-α agents and thiopurines, but only one case was reported in a psoriasis patient worldwide. This difference could be due to a difference in the nature of the inflammatory diseases or a difference in the use of immunomodulators. We investigated the impact of anti-TNF-α agents on the level and repertoire of γδ T cells in peripheral blood from psoriasis patients. Forty-five men and 10 women who were treated with anti-TNF-α agents for psoriasis were monitored median 11 months for the level and clonality of γδ T cells via flow cytometry and PCR analysis of T cell receptor gamma (TCRγ) gene rearrangements. Seventeen men had a repeated analysis within 48 hours of the infliximab infusion to reveal a possible expansion of γδ T cells, as previously observed in CD patients. Ten psoriasis patients who were never exposed to biologicals and 20 healthy individuals served as controls. In the majority of psoriasis patients, the level and clonal pattern of γδ T cells was remarkably stable during infliximab treatment. A single male patient repeatedly experienced a significant increase in the level of γδ T cells after infliximab infusions. A monoclonal γδ T cell repertoire in a polyclonal background tended to be more frequent in anti-TNF-α-treated patients than naïve patients, suggesting that anti-TNF-α therapy may promote the clonal selection of γδ T cells in psoriasis patients.
Original languageEnglish
JournalClinical and Experimental Immunology
Pages (from-to)142–148
Publication statusPublished - 18 Mar 2014

See relations at Aarhus University Citationformats

ID: 72056327